Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT07368270
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
A Prospective, Open-label and Single-arm Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Anti-PD1 armored CD19 CAR-T cells
Updated 1 time since 2026 Last updated: Jan 26, 2026 Started: Jan 31, 2026 Primary completion: Jan 31, 2027 Completion: Jan 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Diffuse Large B Cell Lymphoma and is currently actively recruiting participants. Jiangsu Topcel-KH Pharmaceutical Co., Ltd. leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Data source: Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .